You just read:

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

News provided by

Novartis Pharmaceuticals Corporation

Jun 04, 2016, 16:05 ET